STOCK TITAN

Applied Therapeutics, Inc. - APLT STOCK NEWS

Welcome to our dedicated page for Applied Therapeutics news (Ticker: APLT), a resource for investors and traders seeking the latest updates and insights on Applied Therapeutics stock.

Applied Therapeutics, Inc. (Nasdaq: APLT) is a clinical-stage biopharmaceutical company headquartered at 3104 Cherry Palm Dr, Tampa, FL. The company focuses on creating novel drug candidates targeting validated molecular markers for diseases with high unmet medical needs.

Currently, the company has several promising compounds in its pipeline. The lead candidate is govorestat (AT-007), a central nervous system penetrant Aldose Reductase Inhibitor (ARI) designed to treat rare metabolic diseases like Classic Galactosemia, SORD Deficiency, and PMM2-CDG. Govorestat has shown significant clinical benefits in reducing toxic metabolites like galactitol and sorbitol, leading to improvements in activities of daily living, cognitive skills, and motor functions in both adult and pediatric patients.

In recent achievements, Applied Therapeutics has completed Phase 3 trials for govorestat in treating Classic Galactosemia and SORD Deficiency, receiving Priority Review status for its New Drug Application (NDA) from the U.S. FDA. The company has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). Additionally, Applied Therapeutics is preparing for the commercial launch of govorestat upon potential approval by regulatory authorities.

Other key pipeline candidates include AT-001 for Diabetic Cardiomyopathy (DbCM) and AT-003 for Diabetic Retinopathy. AT-001 has shown favorable results in stabilizing cardiac functional capacity in patients with DbCM and is safe and well-tolerated. AT-003, still in preclinical development, is designed to address diabetic retinopathy.

Financially, Applied Therapeutics reported strong progress, raising $100 million in a private placement to extend its cash runway into 2026. This funding supports its clinical and commercial activities, ensuring sustained growth and development.

To learn more about Applied Therapeutics, visit their official website at www.appliedtherapeutics.com and follow them on Twitter @Applied_Tx.

Rhea-AI Summary
Applied Therapeutics, Inc. will present at the UBS Biopharma Conference 2023 on November 9, 2023, at 2:00 p.m. ET in Miami, Florida. The presentation will be available via live webcast on the company's website, and a replay will be archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
-
Rhea-AI Summary
Applied Therapeutics, Inc. will host a Diabetic Cardiomyopathy expert forum on November 7, 2023. The forum will discuss the disease overview, ARISE-HF trial, and cardiac functional capacity. Key opinion leaders will be present, and the event will be webcast live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
-
Rhea-AI Summary
Applied Therapeutics to present at the 59th EASD Annual Meeting on the potential benefit of AT-001 in treating Diabetic Cardiomyopathy (DbCM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
conferences clinical trial
Rhea-AI Summary
Applied Therapeutics, Inc. plans to submit an NDA for govorestat (AT-007) for the treatment of Galactosemia in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.86%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
-
Rhea-AI Summary
Applied Therapeutics, Inc. plans to hold a Pre-NDA meeting with the FDA this summer to discuss a potential NDA submission for govorestat (AT-007) for the treatment of Classic Galactosemia. The company also plans to submit an EMA Marketing Authorization Application for govorestat in the fall of 2023. Applied Therapeutics believes that the clinical efficacy demonstrated so far, along with biomarker data and a favorable safety profile, may support an NDA submission. The company aims to provide further updates after the meeting with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Applied Therapeutics (APLT)?

The current stock price of Applied Therapeutics (APLT) is $0.8667 as of December 23, 2024.

What is the market cap of Applied Therapeutics (APLT)?

The market cap of Applied Therapeutics (APLT) is approximately 95.2M.

What is the primary focus of Applied Therapeutics, Inc.?

Applied Therapeutics focuses on developing novel drug candidates against validated molecular targets for diseases with high unmet medical needs.

What is govorestat (AT-007)?

Govorestat is a CNS penetrant Aldose Reductase Inhibitor developed for treating rare metabolic diseases like Classic Galactosemia, SORD Deficiency, and PMM2-CDG.

What are the recent achievements of Applied Therapeutics?

Recent achievements include completing Phase 3 trials for govorestat, obtaining FDA Priority Review status for its NDA, and submitting an MAA to the EMA.

What other drugs are in the Applied Therapeutics pipeline?

The pipeline includes AT-001 for Diabetic Cardiomyopathy and AT-003 for Diabetic Retinopathy.

How is govorestat expected to benefit patients with Galactosemia?

Govorestat reduces plasma galactitol levels, improving activities of daily living, cognitive skills, and motor functions in patients with Galactosemia.

What recent financial activities has Applied Therapeutics undertaken?

Applied Therapeutics raised $100 million in a private placement to extend its cash runway into 2026, supporting clinical and commercial activities.

What is the status of govorestat's regulatory review?

Govorestat's NDA is under Priority Review by the FDA with a PDUFA target action date of November 28, 2024. Its MAA is under review by the EMA.

Where is Applied Therapeutics headquartered?

Applied Therapeutics is headquartered at 3104 Cherry Palm Dr, Tampa, FL, United States.

What are AT-001 and AT-003 intended to treat?

AT-001 is developed for Diabetic Cardiomyopathy, and AT-003 is intended for the treatment of Diabetic Retinopathy.

How can I learn more about Applied Therapeutics?

You can learn more by visiting their website at www.appliedtherapeutics.com and following them on Twitter @Applied_Tx.

Applied Therapeutics, Inc.

Nasdaq:APLT

APLT Rankings

APLT Stock Data

95.25M
102.11M
5.24%
101.91%
11.66%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK